ALK and non-small cell lung carcinoma: In ElSayed et al. (2021), mOS was compared between patients with advanced ALK-positive NSCLC who received two or more ALK TKIs and those who received one ALK TKI with chemotherapy or one ALK TKI with no further treatment [66].